Status:

TERMINATED

Post-operative Pain Control With Acetaminophen and Ibuprofen After Functional Endoscopic Sinus Surgery

Lead Sponsor:

University of Illinois at Chicago

Conditions:

Chronic Rhinosinusitis (Diagnosis)

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

The safest and most effective post-operative pain control regimen after functional endoscopic sinus surgery (FESS) has been the subject of persistent research. This prospective study will compare post...

Detailed Description

The safest and most effective post-operative pain control regimen after functional endoscopic sinus surgery (FESS) has been the subject of persistent debate and research for many years. The main reaso...

Eligibility Criteria

Inclusion

  • Males and females ≥18 years of age.
  • Patients of the PI (Dr. Joe) scheduled for sinus surgery at UI Health.
  • Patients with CRS defined as greater than 12 weeks of 2 of the 4 following symptoms: nasal obstruction/congestion, mucopurulent discharge (nasal or postnasal), facial pain/pressure, or decreased/loss of smell + endoscopic/radiographic evidence of disease.
  • CRS patients with or without nasal polyps.
  • Patients who are COVID-19 negative.
  • Patients that understand the purpose and procedures of the study and who agree to participate.
  • Patients who have the capacity to consent autonomously.

Exclusion

  • Males and females \< 18 years of age.
  • Patients of the PI (Dr. Joe) who are not scheduled for sinus surgery at UI Health.
  • Patients who do not have CRS.
  • Patients who have allergies to acetaminophen, ibuprofen, and related non-steroidal anti-inflammatory drugs (NSAIDS).
  • Patients with kidney or liver dysfunction, cirrhosis, metabolic deficiencies, inflammatory bowel disease, peptic ulcer disease, chronic malnutrition, who have had a previous skull base surgery, or who are currently undergoing cancer treatment.
  • Woman who are pregnant or breastfeeding will be excluded.
  • Patients with a history of drug and/or narcotic abuse will be excluded.
  • COVID-19 positive patients.
  • Patients who are not able to understand the purpose and procedures of the study and who do not wish to participate.
  • Patients that do not have the capacity to consent autonomously.

Key Trial Info

Start Date :

July 29 2022

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

June 30 2023

Estimated Enrollment :

60 Patients enrolled

Trial Details

Trial ID

NCT05287217

Start Date

July 29 2022

End Date

June 30 2023

Last Update

May 20 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

University of Illinois at Chicago, Department of Otolaryngology-Head and Neck Surgery

Chicago, Illinois, United States, 60612